Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program

Canada NewsWire March 4, 2015

Resverlogix Presents at BIO CEO & Investor Conference

Canada NewsWire February 10, 2015

Resverlogix Presents at Biotech Showcase During JP Morgan Week

Canada NewsWire January 14, 2015

Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development

Canada NewsWire November 3, 2014

Resverlogix Announces Annual General Meeting Voting Results

Canada NewsWire October 8, 2014

Resverlogix Corporate Update Conference Call & Webcast Announcement

Canada NewsWire October 1, 2014

RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus

Canada NewsWire September 2, 2014

Resverlogix Corp. Closes Additional $30 million from Citibank Loan

Canada NewsWire August 15, 2014

Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan

Canada NewsWire August 13, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus

Canada NewsWire July 23, 2014

Microcap Report: Resverlogix (T.RVX), Virtutone Networks (V.VFX) active

Stockhouse Editorial July 4, 2014

Resverlogix (T.RVX) ups Citibank loan by $30.0 million and shares bump 10%

Stockhouse Editorial July 4, 2014

Resverlogix Secures an Additional $30 million from Citibank Loan

Canada NewsWire July 3, 2014

Resverlogix Closes $2.3 million Private Placement

Canada NewsWire June 11, 2014

Leading Life Science Publication SciBX Highlights RVX-208

Canada NewsWire May 21, 2014

Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014

Canada NewsWire March 31, 2014

Resverlogix Update

Canada NewsWire March 17, 2014

Resverlogix Conference Call & Webcast Announcement

Canada NewsWire February 6, 2014

Resverlogix (T.RVX) jumps 45% on positive RVX-208 trial findings

Gaalen Engen January 15, 2014